AUG 28, 2015 9:39 PM PDT

Promising Drug Target in Pancreatic Cancer Cells

WRITTEN BY: Ilene Schneider
Pancreatic cancer, the fourth deadliest cancer in the U.S., is very hard to detect in its early stages. Rarely diagnosed early and usually spreading rapidly, the disease has a poor prognosis. University of Houston researchers are seeking to develop drugs to enable physicians to prolong patient survival and, possibly, even eradicate pancreatic cancer, according to an article in Drug Discovery & Development
Professor Chin-Yo Lin works with Ph.D. student Sridevi Addanki in his lab at the Center for Nuclear Receptors and Cell Signaling in the College of Natural Sciences and Mathematics at the University of Houston. 
According to cancer biologist Chin-Yo Lin, an assistant professor with the UH Center for Nuclear Receptors and Cell Signaling (CNRCS), "Our research on the role of liver X receptors, or LXRs, in pancreatic cancer cells points to a promising target and strategy in the treatment of pancreatic cancer. We examined the levels of LXRs in patient tumor samples and studied the effects of candidate drug compounds targeting LXRs on cultured pancreatic cancer cells."
 
Lin explained that liver X receptors are key regulators of cholesterol, glucose metabolism and inflammatory response modulation. In collaboration with CNRCS director Dr. Jan-Åke Gustafsson, a pioneer in the discovery of LXRs and the Robert A. Welch Professor in Biology and Biochemistry in the UH College of Natural Sciences and Mathematics, Lin has helped to amass evidence to implicate the involvement of LXRs in numerous malignancies.
 
The researchers expect their ongoing studies to help determine whether LXRs are expressed in all tumors or a specific subset of tumors that could be sensitive to drugs targeting LXRs. Another objective is to determine the effects of the drugs on pancreatic tumors in mouse models that are similar to those found in humans. Eventually, they anticipate using the knowledge from these studies to develop better drugs to target LXRs in pancreatic cancer and other malignancies.
 
The team has done some preliminary studies of LXR expression in patient tumor samples and is preparing to investigate more samples. Recent studies demonstrated that chemical compounds targeting LXRs can retard the growth of tumors in murine models transplanted with human tumor cells.
 
As Lin said, "Our findings point to a class of receptors that can be precisely targeted by drug compounds and are expected to stimulate both basic and translational research on their functions and application as a drug target. Long-term goals are to develop additional drug compounds and clinical testing in human subjects, which will require several more years of research."
 
He concluded, "Our next steps are to collect more information from patient samples and data from pre-clinical studies. Based on the results, we will then move forward with clinical studies using existing compounds or partner with biotech or pharmaceutical companies to develop better drug candidates."
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 17, 2020
Cardiology
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
SEP 17, 2020
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
One of the biggest issues with chemotherapy treatments is their inherent toxicities. Most chemotherapy drugs are toxic t ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
NOV 02, 2020
Cancer
Age impacts response to melanoma treatment
NOV 02, 2020
Age impacts response to melanoma treatment
Research from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health& ...
NOV 03, 2020
Genetics & Genomics
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
NOV 03, 2020
One Eight Cancer Patients Also Carry Inherited Genetic Mutations
Genetic sequencing technologies have rapidly advanced, reducing the time required to sequence the entire human genome fr ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
Loading Comments...